Positron Emission Tomography study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to healthy participants and patients with Crohn’s disease

Study identifier:D9690C00004

ClinicalTrials.gov identifier:NCT06053424

EudraCT identifier:N/A

CTIS identifier:2023-505471-78-00

Recruitment Complete

Official Title

A Phase 1b Open Label Positron Emission Tomography Study to Assess Changes in Abdominal [11C]AZ14132516 Uptake Following Administration of Single Doses of AZD7798 to Healthy Participants and Patients with Crohn’s Disease

Medical condition

Crohn’s disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7798, [11C]AZ14132516

Sex

All

Actual Enrollment

11

Study type

Interventional

Age

20 Years - 65 Years

Date

Study Start Date: 25 Sept 2023
Estimated Primary Completion Date: 11 Oct 2024
Estimated Study Completion Date: 11 Oct 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria